![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Equasens | EU:EQS | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.10 | 2.19% | 51.40 | 51.20 | 51.60 | 52.00 | 50.70 | 50.70 | 3,626 | 16:35:06 |
Villers-lès-Nancy, 24 March 2023 - 6:00 p.m. (CET)
PRESS RELEASE
2022 Net Profit: +18.35% to €48.70m
In €m | 2021 | 2022 | Change2022/2021 |
Revenue | 193.07 | 214.07 | 10.88% |
Current Operating Income | 50.45 | 56.79 | 12.57% |
Net Profit | 41.15* | 48.70** | 18.35% |
Net Profit attributable to the Group | 39.12 | 46.38 | 18.56% |
Basic earnings per share (in €) | 2.60 | 3.09 | 18.52% |
* Of which IP BOX 2021: €2.94m** Of which net IP BOX 2022: €7.74m
Under the chairmanship of Thierry CHAPUSOT, the Board of Directors met on 24 March 2023, in the presence of the Statutory Auditors, to examine and approve the accounts for fiscal 2022. The audit procedures for the consolidated accounts have been performed. The auditors' report will be issued after the management report has been reviewed and the procedures for filing the annual financial report have been completed.
Group Equasens reported annual revenue of €214.07m up 10.88% from 31 December 2021. Like-for-like (incl. PROKOV Editions in Q4), FY 2022 revenue rose 8.82% to €210.09m. The Group confirms the efficiency of its strategy of promoting interoperability between healthcare professionals and establishments, with the priorities of structuring the healthcare offer, improving coordination between healthcare professionals and exchanging patient data.
Current Operating Income for the Group totalled €56.79m, up 12.57% from 2021. By Division, Current Operating Income broke down as follows:
Net Profit rose by 18.35% to €48.70m, including €7.74m from net IP BOX.
Basic earnings per share rose 18.52% to €3.09 (€2.60 in 2021).
With respect to its balance sheet, the Group continues to benefit from its strong investment capacity with a gross cash position of €119.20m at 31 December 2022. In addition, at 31/12/2022, the company held 142,428 own shares valued at €10.02m.
Shareholders' equity stood at €196.80m at 31 December 2022 compared to €165.24m at the end of 2021. The Group confirms its growth potential supported by its strong cash position, with 17.07% growth in cash flow to €62.05m and a reduction in financial liabilities.
For more than 10 years, Equasens Group has been creating shareholder value and maintained its efforts to distribute dividends. The Group will propose to the Annual General Meeting on 29 June 2023 a gross dividend per share of €1.15 (+9.52%).
2022 confirmed the efficiency of the Equasens Group's growth strategy (organic and external) and the qualification of its software products for the Ségur programme attests to its know-how and technological expertise.
The Group also confirms its financial solidity (no net debt and a positive net cash position of €56.26m) ensuring it the resources to achieve its goals for expansion in Europe and develop in other areas of the healthcare sector.
Upcoming events
About Group Equasens
With more than 1,200 employees fulfilling a vital role as “Citizens in the Service of Health and Well-Being”, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.
With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.
Listed on Euronext Paris™ - Compartment A
Included in the Euronext Tech Leaders segment and the European Rising Tech label Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).ISIN: FR0012882389 - Ticker Code: EQS
For all the latest news on Equasens Group go to www.equasens.com
CONTACTS
Analyst and Investor Relations: Chief Administrative and Financial Officer: Frédérique SCHMIDTTel. +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Media Relations:FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr
Attachment
1 Year Equasens Chart |
1 Month Equasens Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions